AXL expression in LADs by IHC.

<p>AXL expression status was classified in four categories, 0 (negative, A), 1+ (weak, B), 2+ (moderate, C), and 3+ (strong, D). All images include vascular endothelial cells, which were used as internal controls.</p

Results of target sequencing for 22 genes in AXL 3+-expressing lung adenocarcinomas from 12 patients.

<p>Results of target sequencing for 22 genes in AXL 3+-expressing lung adenocarcinomas from 12 patients.</p

Overall survival of the patients based on AXL expression status.

<p>Overall survival rates correlated with AXL expression status. The group of patients whose specimens showed strong AXL expression (3+ intensity) showed markedly shorter survival than groups whose specimens showed weaker intensity (0, 1+ or 2+; <i>P</i> = 0.0033; log-rank test). 5ysr: 5-year survival rates.</p

Relationships between AXL expression and markers for EMT and CSCs.

<p>Relationships between AXL expression and markers for EMT and CSCs.</p

Relationships between AXL expression and clinical factors in 161 LAD specimens.

<p>Relationships between AXL expression and clinical factors in 161 LAD specimens.</p

A case of AXL 3+-expressing lung adenocarcinoma that responded well to gefitinib.

<p>(A) Pre-treatment and (B) post-treatment (6 months after initiation of gefitinib, CT scans are shown.</p